<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04134663</url>
  </required_header>
  <id_info>
    <org_study_id>UESTC-neuSCAN-43</org_study_id>
    <nct_id>NCT04134663</nct_id>
  </id_info>
  <brief_title>Comparison of Intranasal Oxytocin Effects Using Co-administration With a Vasoconstrictor</brief_title>
  <official_title>Comparison of Direct and Indirect Effects of Intranasal Oxytocin Using Co-administration With a Vasoconstrictor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Electronic Science and Technology of China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Electronic Science and Technology of China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to dissociate direct from indirectly mediated effects of intranasal oxytocin
      administration by using treatment with or without prior intranasal administration of a
      vasoconstrictor to reduce peripheral increases in peptide concentrations. Primary outcomes of
      the randomized placebo-controlled double-blind experiment are blood oxytocin concentration
      and oxytocin-associated responses in central and peripheral systems.

      Intranasal application of the neuropeptide oxytocin has been reported to produce a number of
      neural, physiological and behavior effects which may be of potential therapeutic relevance,
      but it is unclear the extent to which they are mediated directly via the peptide entering the
      brain or indirectly as a result of increased peripheral concentrations. In the current
      placebo-controlled, double blind experiment on healthy adult male subjects the investigators
      will measure the effects of a single dose of intranasal oxytocin (24IU) on brain activity
      (using electroencephaolography - EEG) as well as on cardiac (heart-rate and heart-rate
      variablility) and gastric (electrogastrogram - EGG) activity and physiological arousal (skin
      conductance response - SCR). The pattern of functional effects observed will be compared with
      subjects receiving intranasal pretreatment with a vasoconstrictor prior to oxytocin in order
      to reduce the amount of oxytocin entering the peripheral circulation. The investigators
      hypothesize that prior administration of the vasoconstrictor will greatly reduce blood
      oxytocin concentrations following intranasal oxytocin treatment. Where neural/physiological
      effects are also affected, this will indicate an indirectly mediated action of intranasally
      administered oxytocin whereas if they are not this will indicate a directly mediated action.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 18, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood oxytocin concentration</measure>
    <time_frame>2 hours</time_frame>
    <description>blood oxytocin concentration changes following vasoconstrictor/placebo and oxytocin/placebo treament</description>
  </primary_outcome>
  <primary_outcome>
    <measure>resting EEG time-frequency</measure>
    <time_frame>2 hours</time_frame>
    <description>resting EEG time-frequency changes following vasoconstrictor/placebo and oxytocin/placebo treament</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>heartrate</measure>
    <time_frame>2 hours</time_frame>
    <description>heartrate (and heartrate variability) changes following vasoconstrictor/placebo and oxytocin/placebo treament</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skin conductance</measure>
    <time_frame>2 hours</time_frame>
    <description>skin conductance level (measured by skin conductance response) changes following vasoconstrictor/placebo and oxytocin/placebo treament</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gastrointestinal activity</measure>
    <time_frame>2 hours</time_frame>
    <description>gastrointestinal activity (measured by electrogastrogram) changes following vasoconstrictor/placebo and oxytocin/placebo treament</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>vasoconstrictor + intranasal oxytocin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects receive the vasoconstrictor followed by oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vasoconstrictor's placebo + intranasal oxytocin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects receive the vasoconstrictor's placebo followed by oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vasoconstrictor + intranasal oxytocin placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subjects receive the vasoconstrictor followed by intranasal oxytocin's placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vasoconstrictor and oxytocin treatment</intervention_name>
    <description>intransal administration of vasoconstrictor and oxytocin</description>
    <arm_group_label>vasoconstrictor + intranasal oxytocin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vasoconstrictor's placebo and oxytocin treatment</intervention_name>
    <description>intransal administration of vasoconstrictor's placebo and oxytocin</description>
    <arm_group_label>vasoconstrictor's placebo + intranasal oxytocin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vasoconstrictor and oxytocin's placebo treatment</intervention_name>
    <description>intransal administration of vasoconstrictor and oxytocin's placebo</description>
    <arm_group_label>vasoconstrictor + intranasal oxytocin placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects without past or current psychiatric or neurological disorders

        Exclusion Criteria:

          -  history of head injury

          -  medical or psychiatric illness.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shuxia Yao</last_name>
    <phone>+8618111297596</phone>
    <email>yaoshuxia@uestc.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>school of life science and technology, University of Electronic Science and Technology of China</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qin Li, Master</last_name>
      <email>helenlee@uestc.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Electronic Science and Technology of China</investigator_affiliation>
    <investigator_full_name>Keith Kendrick</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>vasoconstrictor</keyword>
  <keyword>oxytocin</keyword>
  <keyword>EEG</keyword>
  <keyword>peripheral nervous system response</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Vasoconstrictor Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

